HOMOCYSTINURIA
Clinical trials for HOMOCYSTINURIA explained in plain language.
Never miss a new study
Get alerted when new HOMOCYSTINURIA trials appear
Sign up with your email to follow new studies for HOMOCYSTINURIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a Lab-Made enzyme tame a rare genetic disorder?
Disease control Recruiting nowThis trial tests whether pegtibatinase, a lab-made version of the CBS enzyme, can safely lower homocysteine levels in people with classical homocystinuria (HCU), a rare genetic condition that causes harmful buildup of homocysteine and methionine. The study includes children and a…
Matched conditions: HOMOCYSTINURIA
Phase: PHASE1, PHASE2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New shot could tame rare metabolic disease
Disease control Recruiting nowThis Phase 3 trial tests pegtibatinase, an enzyme given as a shot, in 70 people aged 12–65 with classical homocystinuria. The goal is to see if it safely lowers high homocysteine levels when added to standard care. Participants receive either the drug or a placebo for 24 weeks.
Matched conditions: HOMOCYSTINURIA
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC